Compositions and methods for treating cancer
US-2020290978-A1 · Sep 17, 2020 · US
Compositions and methods for treating cancer
US11377451B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11377451-B2 |
| Application number | US-202117475144-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 14, 2021 |
| Priority date | Mar 15, 2019 |
| Publication date | Jul 5, 2022 |
| Grant date | Jul 5, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to compounds, compositions and methods for treating cancer, including compounds that are capable of penetrating the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating cancer in the brain, including glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of treating cancers such as glioblastoma and other EGFR mediated cancers that have been determined to have altered glucose metabolism in the presence of inhibitors. The present disclosure also provides methods of administering to a subject a glucose metabolism inhibitor and a cytoplasmic p53 stabilizer.
First claim
Opening claim text (preview).
We claim: 1. A compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1 , wherein the compound is 3. The compound of claim 1 , wherein the compound is 4. The compound of claim 1 , wherein the compound is 5. The compound of claim 1 , wherein the compound is 6. The compound of claim 1 , wherein the compound is 7. The compound of claim 1 , wherein the compound is 8. The compound of claim 1 , wherein the compound is 9. The compound of claim 1 , wherein the compound is 10. The compound of claim 1 , wherein the compound is 11. The compound of claim 1 , wherein the compound is 12. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is 13. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is 14. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is 15. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is 16. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is 17. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is 18. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is 19. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is 20. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is 21. The compound of claim 1 , wherein the compound is a pharmaceutically acceptable salt of the compound which is 22. A pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt thereof, of claim 1 and a pharmaceutically acceptable excipient.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
directly linked by a ring-member-to-ring-member bond · CPC title
with hetero atoms directly attached in positions 2 and 4 · CPC title
- C07D491/056Primary
with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring · CPC title
not condensed and containing further heterocyclic rings, e.g. timolol · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11377451B2 cover?
- The present disclosure relates to compounds, compositions and methods for treating cancer, including compounds that are capable of penetrating the blood brain barrier to modulate the activity of EGFR tyrosine kinase. The disclosure further relates to methods of treating cancer in the brain, including glioblastoma and other EGFR mediated cancers. The disclosure further relates to methods of trea…
- Who is the assignee on this patent?
- Univ California
- What technology area does this patent fall under?
- Primary CPC classification C07D491/056. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 05 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).